EUVIMEDObjevte EUVIMED
Crossref

Pharmacological Effects of a New Soluble Guanylate Cyclase Stimulator in Experimental Ischemic Stroke

V V Bykov, A V Bykova, V S Motov, V V Larchenko, G A Chernysheva, V I Smol'yakova, O I Aliev, V A Khazanov, A I Vengerovskii, V V Udut

Bulletin of Experimental Biology and Medicine · 2023

DOI: 10.1007/s10517-023-05938-4 ↗

At a glance

Journal article in Bulletin of Experimental Biology and Medicine, 2023. Written by V V Bykov and 9 co-authors. Institution: IPHAR (Innovative Pharmacology Research, LLC), Tomsk, Russia. vladimir.b.1989@gmail.com. Major MEDLINE topics: Ischemic Stroke, Brain Ischemia, Stroke. Cited 1 times so far (Crossref); 13 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

We studied the action of a new indolinone derivative GRS, acetylsalicylic acid (ASA), and their combination on platelet aggregation, vasodilatory endothelial function, neurological status, and cerebral infarction area in experimental focal cerebral ischemia/reperfusion in rats. GRS compound (10 mg/kg), ASA (10 mg/kg), and their combination in the same doses were administered orally once a day as a suspension in 1% starch solution over 5 days after pathology modeling. Sham-operated and control animals were administered 1% starch solution. On day 5 after pathology modeling, platelet aggregation and brain damage area were studied in a half of rats in each group, and the vasodilatory function of the endothelium was studied in the other half. Neurological deficit was assessed 4 h and 1, 3, and 5 days after pathology modeling. GRS compound and ASA equally effectively prevent platelet aggregation and the development of neurological deficit in rats. GRS compound restores the vasodilatory effects of the endothelium, but only ASA contributes to reduction of the cerebral infarction area. In case of combined administration, GRS and ASA do not exhibit synergy in their antiaggregant effect.

Subjects

MeSH terms (MEDLINE)

Ischemic StrokeBrain IschemiaStrokeRatsAnimalsPlatelet Aggregation InhibitorsSoluble Guanylyl CyclaseAspirinPlatelet AggregationVasodilator AgentsCerebral InfarctionStarch

Author keywords

endothelial dysfunctionexperimental model of ischemic strokeindolinone derivativeplatelet aggregationsoluble guanylate cyclase stimulator

Substances

Platelet Aggregation InhibitorsSoluble Guanylyl CyclaseAspirinVasodilator AgentsStarch

Authors and institutions

  • IPHAR (Innovative Pharmacology Research, LLC), Tomsk, Russia. vladimir.b.1989@gmail.com.
  • Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia. vladimir.b.1989@gmail.com.
  • IPHAR (Innovative Pharmacology Research, LLC), Tomsk, Russia.
  • Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia.
  • E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

Cite

APA

Bykov, V. V., Bykova, A. V., Motov, V. S., Larchenko, V. V., Chernysheva, G. A., Smol'yakova, V. I., Aliev, O. I., Khazanov, V. A., Vengerovskii, A. I., & Udut, V. V. (2023). Pharmacological Effects of a New Soluble Guanylate Cyclase Stimulator in Experimental Ischemic Stroke. Bulletin of Experimental Biology and Medicine. https://doi.org/10.1007/s10517-023-05938-4

Vancouver

Bykov VV, Bykova AV, Motov VS, Larchenko VV, Chernysheva GA, Smol'yakova VI, et al. Pharmacological Effects of a New Soluble Guanylate Cyclase Stimulator in Experimental Ischemic Stroke. Bulletin of Experimental Biology and Medicine. 2023. doi:10.1007/s10517-023-05938-4

BibTeX
@article{Bykov2023,
  author = {Bykov, V V and Bykova, A V and Motov, V S and Larchenko, V V and Chernysheva, G A and Smol'yakova, V I and Aliev, O I and Khazanov, V A and Vengerovskii, A I and Udut, V V},
  title = {Pharmacological Effects of a New Soluble Guanylate Cyclase Stimulator in Experimental Ischemic Stroke},
  journal = {Bulletin of Experimental Biology and Medicine},
  year = {2023},
  doi = {10.1007/s10517-023-05938-4}
}
Start for free →